Early monitoring of infliximab serum trough levels predicts long-term therapy failure in patients with axial spondyloarthritis-Reference-Cited by-同舟云学术

Early monitoring of infliximab serum trough levels predicts long-term therapy failure in patients with axial spondyloarthritis

Published:2021-06-29 Issue: Volume: Page:1-8
ISSN:0300-9742
Container-title:Scandinavian Journal of Rheumatology
language:en
Short-container-title:Scandinavian Journal of Rheumatology

Author:

Martínez-Feito A¹²,Navarro-Compán V²³,Hernández-Breijo B²,Olariaga-Mérida E²,Peiteado D²³,Villalba A²³,Nuño L²³,Monjo I²³,Diego C¹,Pascual-Salcedo D²,Nozal P¹,Balsa A²³,Plasencia-Rodríguez C²³

Affiliation:

1. Immunology Unit, La Paz University Hospital, Madrid, Spain

2. Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research, Madrid, Spain

3. Rheumatology Department, La Paz University Hospital, Madrid, Spain

Publisher

Informa UK Limited

Subject

Immunology,General Medicine,Immunology and Allergy,Rheumatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/03009742.2021.1914430

Reference40 articles.

1. Biologics in spondyloarthritis: TNFα inhibitors and other agents

2. Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review

3. Anti‐drug antibodies and low serum trough infliximab levels correlate with disease activity measures in spondyloarthritis patients on an as‐needed infliximab treatment

4. Therapeutic drug monitoring of infliximab in spondyloarthritis. A review of the literature

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology;Therapeutic Drug Monitoring;2024-04-17